<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Saudi J Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">Saudi J Gastroenterol</journal-id><journal-id journal-id-type="publisher-id">SJG</journal-id><journal-title-group><journal-title>Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association</journal-title></journal-title-group><issn pub-type="ppub">1319-3767</issn><issn pub-type="epub">1998-4049</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4991199</article-id><article-id pub-id-type="pmid">27488323</article-id><article-id pub-id-type="publisher-id">SJG-22-288</article-id><article-id pub-id-type="doi">10.4103/1319-3767.187602</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Significance of BMI1 and FSCN1 Expression in Colorectal Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Alajez</surname><given-names>Nehad M.</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1">Stem Cell Unit, Department of Anatomy, College of Medicine, King Saud University, Riyadh - 11461, Kingdom of Saudi Arabia</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Prof. Nehad M. Alajez, Stem Cell Unit, Department of Anatomy, College of Medicine, King Saud University, Riyadh 11461, Kingdom of Saudi Arabia. E-mail: <email xlink:href="nalajez@ksu.edu.sa">nalajez@ksu.edu.sa</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Aug</season><year>2016</year></pub-date><volume>22</volume><issue>4</issue><fpage>288</fpage><lpage>293</lpage><history><date date-type="received"><day>25</day><month>11</month><year>2015</year></date><date date-type="accepted"><day>18</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Saudi Journal of Gastroenterology</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Background/Aims:</title><p>Colorectal cancer (CRC) is the third most common type of cancer in terms of incidence and the fourth in cause of death world-wide, underscoring the need to identify novel biomarkers for early diagnosis, as well as improved disease stratification and treatment choices.</p></sec><sec id="st2"><title>Patients and Methods:</title><p>The Gene Expression Omnibus (GSE21510) and the Cancer Genome Atlas (TCGA) CRC datasets were utilized in the current study. GeneSpring 13.0 was used for normalization and analysis. The log-rank test was used to compare the outcome between expression groups.</p></sec><sec id="st3"><title>Result:</title><p>Significant upregulation of BMI1 (2.3 FC, <italic>P</italic> = 3.7 &#x000d7; 10<sup>-18</sup>) and FSCN1 (1.3 FC,P = 4.7 &#x000d7; 10<sup>-3</sup>) was observed in CRC. High BMI1 expression was associated with reduced overall survival (OS) [Hazard ratio (HR), 1.87; 95% CI. 1.17&#x02013;3.03; <italic>P</italic> = 0.009] and reduced disease-free survival (DFS) [HR, 162; 95% CI 1.01&#x02013;2.63;P = 0.045]. Similarly, high expression of FSCN1 was associated with reduced OS (HR, 2.0; 95% CI, 1.24&#x02013;3.2; <italic>P</italic> = 0.0044) and reduced DFS (HR, 1.60; 95% CI, 0.99&#x02013;2.57;P = 0.055). Importantly, BMI1<sup>high</sup>/FSCN1<sup>high</sup> patients experienced the worst OS (HR, 3.17; 95% CI, 1.77&#x02013;6.15; <italic>P</italic> = 0.0002) and DFS (HR, 2.34; 95% CI, 1.27&#x02013;4.67,P = 0.0078). Using pathway analyses, tumors overexpressing BMI1 were enriched in zinc finger proteins and genes involved in DNA binding and regulation of transcription, whereas tumors expressing FSCN1 were enriched in genes involved in cell migration.</p></sec><sec id="st4"><title>Conclusion:</title><p>Our data revealed poor OS and DFS in CRC patients overexpressing BMI1 or FSCN1 and suggest that these two markers in combination may represent superior prognostic marker to either one. Targeting BMI1 and FSCN1 may also provide potential therapeutic opportunity in CRC.</p></sec></abstract><kwd-group><title>Key Words</title><kwd>BMI1</kwd><kwd>CRC</kwd><kwd>FSCN1</kwd><kwd>survival</kwd></kwd-group></article-meta></front><body><p>Colorectal cancer (CRC) is among the most prevalent types of cancers causing high mortality rates globally. It is ranked as the third leading cause of death in both genders.[<xref rid="ref1" ref-type="bibr">1</xref>] In the Kingdom of Saudi Arabia, CRC is the most common cancer type in men and the second most common in women.[<xref rid="ref2" ref-type="bibr">2</xref>] The 5-year overall survival (OS) has been reported to be ~63% for patients with localized disease, ~50% for patients with regional disease, and ~15% for patients with distant metastases.[<xref rid="ref2" ref-type="bibr">2</xref>] Several genes have been implicated in CRC development and therapy failure. Polycomb group (PcG) family of genes has recently emerged as key regulators of cancer development and progression, which function by forming several multimeric polycomb repressive complexes, such as PRC1 and PRC2.[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref>] PRC1, also referred to as the &#x0201c;maintenance complex,&#x0201d; contains the BMI1 proto-oncogene.[<xref rid="ref5" ref-type="bibr">5</xref>] In addition to their role during development, different members of the PcG gene family have altered expression in different cancer types. We previously reported a novel role for BMI1 polycomb gene in promoting cancer cell survival through inhibition of the p53-dependant cell death.[<xref rid="ref6" ref-type="bibr">6</xref>] BMI1 expression has been linked to the cancer stem cell phenotype and its expression was correlated with disease progression and poor clinical outcome in different human malignancies.[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref>] Our recent work revealed multiple dysregulated networks in CRC in Saudi Arabia, affecting different cellular processes and pathways (cell cycle, integrated cancer, Wnt, matrix metalloproteinase, and TGF-&#x003b2;).[<xref rid="ref10" ref-type="bibr">10</xref>] Among the identified genes, we found FSCN1 to be upregulated in CRC compared to adjacent normal tissue (<inline-supplementary-material xlink:title="local_file" xlink:href="SJG-22-288_Suppl1.tif" xlink:type="simple" id="d36e177" content-type="local-data">Supplementary Figure 1</inline-supplementary-material>). FSCN1 is an actin-binding protein which is oftentimes upregulated in different human cancers.[<xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref>] In particular, overexpression of FSCN1 promoted cancer cell migration, invasion, and metastasis <italic>in vitro</italic> and <italic>in vivo</italic>.[<xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref15" ref-type="bibr">15</xref>] While various studies have examined the expression of BMI1 or FSCN1 in various human cancers, none to-date has examined the coexpression of BMI1 and FSCN1 in CRC and identified the molecular phenotype of BMI1 and FSCN1 expressing tumors. In the current study, we assessed the expression and clinical significance of BMI1 and FSCN1 in two different CRC cohorts and revealed the molecular phenotype of tumors expressing these two markers.</p><supplementary-material content-type="local-data" id="S5"><label>Supplementary Figure 1</label><caption><p>Box and whiskers plot depicting significant upregulation of FSCN1 in CRC patients (<italic>n</italic>=13) compared to adjacent normal tissue (<italic>n</italic>=13) based on microarray expression. Data are presented as log2 mRNA expression</p></caption><media xlink:href="SJG-22-288_Suppl1.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><sec sec-type="materials|methods" id="sec1-1"><title>MATERIALS AND METHODS</title><sec id="sec2-1"><title>Patient information and data analysis</title><p>The current study was conducted on two different CRC cohorts. First, the NCBI Gene Expression Omnibus (GEO) dataset (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/gds">http://www.ncbi.nlm.nih.gov/gds</ext-link>, GSE21510 was utilized to compare the expression of BMI1 and FSCN1 in CRC (<italic>n</italic> = 123) to normal controls (<italic>n</italic> = 25). Second, log2 normalized RNAseq expression data were retrieved from a total of 360 colorectal cancer patients from the Cancer Genome Atlas (TCGA) portal (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.gov">http://www.cbioportal.gov</ext-link>), as described before.[<xref rid="ref16" ref-type="bibr">16</xref><xref rid="ref17" ref-type="bibr">17</xref>] Patients were subsequently divided into high and low according to the median expression of BMI1 or FSCN1, as we previously described.[<xref rid="ref4" ref-type="bibr">4</xref>] The clinical characteristics of the TCGA dataset are shown in <xref ref-type="table" rid="T1">Table 1</xref>. The clinical characteristics for the GSE21510 has been described before.[<xref rid="ref18" ref-type="bibr">18</xref>] The clinical characteristics for patients from the King Khalid University Hospital dataset were previously described.[<xref rid="ref10" ref-type="bibr">10</xref>]</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>The Cancer Genome Atlas dataset patient and tumor characteristics</p></caption><graphic xlink:href="SJG-22-288-g002"/></table-wrap></sec><sec id="sec2-2"><title>Microarray data analysis</title><p>Raw gene expression microarray data were retrieved from the GEO (GSE21510) and were imported into GeneSpring 13.0 (Agilent Technologies, Palo Alto, CA, USA). Raw data were subsequently normalized using percentile Shift, whereas Benjamini&#x02013;Hochberg False Discovery Rate (FDR) method was used for multiple testing corrections. Two-fold cutoff and <italic>P</italic> (corr) &#x0003c; 0.05 were used to determine significantly changed transcripts.</p></sec><sec id="sec2-3"><title>Statistical analysis</title><p>Survival curve comparison was conducted using the log-rank (Mantel&#x02013;Cox) test. Unpaired two-tailed <italic>t</italic>-test and <italic>P</italic> value of &#x0003c;0.05 was considered significant. Pearson correlation was used to identify genes with similar expression pattern to that of BMI1 or FSCN1 in CRC. Mukaka[<xref rid="ref19" ref-type="bibr">19</xref>] has previously suggested using 0.3 correlation coefficient for Pearson correlation studies, hence a correlation of &#x02265;0.3 cutoff was considered significant. Pathway analyses were conducted using The Database for Annotation, Visualization and Integrated Discovery functional annotation and clustering bioinformatics tool, as we previously described.[<xref rid="ref4" ref-type="bibr">4</xref>] Statistical analyses and graphing were performed using Graphpad Prism 6.0 software (Graphpad<sup>&#x000ae;</sup> Software, San Diego, CA, USA).</p></sec></sec><sec sec-type="results" id="sec1-2"><title>RESULTS</title><sec id="sec2-4"><title>BMI1 and FSCN1 are overexpressed in colorectal cancer</title><p>The expression level of BMI1 and FSCN1 were assessed in a cohort of 123 CRC and 25 normal subjects retrieved from the GEO (GSE21510). Data presented in <xref ref-type="fig" rid="F1">Figure 1a</xref> and <xref ref-type="fig" rid="F1">b</xref> revealed significant upregulation of BMI1 (2.3 FC, <italic>P</italic> = 3.7 &#x000d7; 10<sup>-18</sup>) and FSCN1 (1.3 FC, <italic>P</italic> = 4.7 &#x000d7; 10<sup>-3</sup>) in CRC, respectively.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>BMI1 and FSCN1 are overexpressed in colorectal cancer. (a) Scatter plot depicting significant upregulation of BMI1 in colorectal cancer patients (<italic>n</italic> = 123) compared to normal tissue (<italic>n</italic> = 25) based on microarray expression. (b) FSCN1 is significantly upregulated in colorectal cancer patients (<italic>n</italic> = 123) compared to normal tissue (<italic>n</italic> = 25) based on microarray expression</p></caption><graphic xlink:href="SJG-22-288-g003"/></fig></sec><sec id="sec2-5"><title>Expression of BMI1 and FSCN1 correlates with poor clinical outcome</title><p>We subsequently sought to assess the significance of overexpression of BMI1 and FSCN1 in CRC. Therefore, the expression of BMI1 and FSCN1 was interrogated in the TCGA CRC cohort (360 patients). When the patients were divided into two groups according to the median expression, patients with BMI1<sup>high</sup> exhibited significantly lower OS [56.2 month median survival for BMI1<sup>high</sup> vs. 99.9 month for BMI1<sup>low</sup>; HR, 1.87; 95% confidence interval, 1.17&#x02013;3.03; <italic>P</italic> = 0.009, log-rank (Mantel&#x02013;Cox) test; <xref ref-type="fig" rid="F2">Figure 2a</xref>]. Similarly, patients with FSCN1<sup>high</sup> exhibited significantly lower OS [67.3 month median survival for FSCN1<sup>high</sup> vs. 92.7 month for FSCN1<sup>low</sup>; HR, 2.0; 95% confidence interval, 1.24&#x02013;3.20; <italic>P</italic> = 0.0044, log-rank (Mantel&#x02013;Cox) test; <xref ref-type="fig" rid="F2">Figure 2b</xref>]. DFS also followed similar trends where BMI1<sup>high</sup> patients exhibited significantly lower DFS [37.0 month median survival for BMI1<sup>high</sup> vs. 109.0 month for BMI1<sup>low</sup>; HR, 1.62; 95% confidence interval, 1.01&#x02013;2.63; <italic>P</italic> = 0.045, log-rank (Mantel&#x02013;Cox) test; <xref ref-type="fig" rid="F3">Figure 3a</xref>]. FSCN1<sup>high</sup> patients showed significantly lower DFS [74.6 month median survival for FSCN1<sup>high</sup> vs. 109.0 month for FSCN1<sup>low</sup>; HR, 1.60; 95% confidence interval, 0.99&#x02013;2.57; <italic>P</italic> = 0.055, log-rank (Mantel&#x02013;Cox) test; <xref ref-type="fig" rid="F3">Figure 3b</xref>].</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Poor overall survival in colorectal cancer patients overexpressing BMI1 or FSCN1. Kaplan&#x02013;Meier plot of overall survival in the The Cancer Genome Atlas colorectal cancer cohort as a function of (a) BMI1 or (b) FSCN1 expression, divided according to median expression. Log-rank (Mantel&#x02013;Cox) test was used to calculate statistical significance</p></caption><graphic xlink:href="SJG-22-288-g004"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Poor disease free survival in colorectal cancer patients overexpressing BMI1 or FSCN1. Kaplan&#x02013;Meier plot of disease free survival in the The Cancer Genome Atlas colorectal cancer cohort as a function of (a) BMI1 or (b) FSCN1 expression, divided according to median expression. Log-rank (Mantel&#x02013;Cox) test was used to calculate statistical significance</p></caption><graphic xlink:href="SJG-22-288-g005"/></fig></sec><sec id="sec2-6"><title>Combination of BMI1 and FSCN1 expression has more predictive value than each marker alone</title><p>We subsequently assessed the predictive value of the combination of BMI1 and FSCN in CRC. Interestingly, BMI1<sup>high</sup>/FSCN1<sup>high</sup> tumors were associated with reduced OS [47.0 month median survival for BMI1<sup>high</sup>/FSCN1<sup>high</sup> vs. &#x0003e;139.0 month for BMI1<sup>low</sup>/FSCN1<sup>low</sup>; HR, 3.17; 95% confidence interval, 1.77&#x02013;6.15; <italic>P</italic> = 0.0002, log-rank (Mantel&#x02013;Cox) test; <xref ref-type="fig" rid="F4">Figure 4a</xref>] and reduced DFS [55.1 month median survival for BMI1<sup>high</sup>/FSCN1<sup>high</sup> vs. &#x0003e;109.0 month for BMI1<sup>low</sup>/FSCN1<sup>low</sup>; HR, 2.34; 95% confidence interval, 1.27&#x02013;4.67, <italic>P</italic> = 0.0078, log-rank (Mantel&#x02013;Cox) test; <xref ref-type="fig" rid="F4">Figure 4b</xref>]. Therefore, the combination of BMI1 and FSCN1 demonstrated better prognostic value than the utilization of each marker alone (compare <xref ref-type="fig" rid="F4">Figure 4</xref> to Figures <xref ref-type="fig" rid="F2">2</xref> and <xref ref-type="fig" rid="F3">3</xref>).</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>Combination of BMI1 and FSCN1 expression has higher predictive value than either marker alone. Kaplan&#x02013;Meier plot of (a) overall survival or (b) disease free survival, in the The Cancer Genome Atlas colorectal cancer cohort as a function of BMI1/FSCN1 expression comparing BMI1<sup>high</sup>/FSCN1<sup>high</sup> to BMI1<sup>low</sup>/FSCN1<sup>low</sup>, divided according to median expression. Log-rank (Mantel&#x02013;Cox) test was used to calculate statistical significance</p></caption><graphic xlink:href="SJG-22-288-g006"/></fig></sec><sec id="sec2-7"><title>Pathway analysis revealed the molecular phenotype of BMI1 and FSCN1 expressing colorectal cancer tumors</title><p>We subsequently sought to determine the molecular phenotype of BMI1 vs. FSCN1 expressing tumors in CRC. Using network analysis, BMI1 and FSCN1 were found to be at the center of two overlapping cellular networks [<xref ref-type="fig" rid="F5">Figure 5a</xref>]. Using Pearson correlation (&#x02265;0.3), we identified 425 genes whose expression followed similar pattern to that of BMI1 in CRC [<inline-supplementary-material xlink:title="local_file" xlink:href="SJG-22-288_Suppl1.pdf" xlink:type="simple" id="d36e497" content-type="local-data">Supplementary Table 1</inline-supplementary-material>]. Functional annotation and clustering analysis performed on this gene list revealed prominent enrichment in zinc finger and DNA binding protein and those genes involved in the regulation of gene expression. On the other hand, Pearson correlation identified 602 genes whose expression positively correlated with FSCN1 expression in CRC [<inline-supplementary-material xlink:title="local_file" xlink:href="SJG-22-288_Suppl2.pdf" xlink:type="simple" id="d36e500" content-type="local-data">Supplementary Table 2</inline-supplementary-material>]. Functional annotation and clustering analysis on the identified gene list revealed prominent enrichment in genes involved in regulating cell migration.</p><fig id="F5" position="float"><label>Figure 5</label><caption><p>Molecular characterization of BMI1 and FSCN1 expressing colorectal cancer. (a) Network analysis performed on BMI1 and FSCN1 in colorectal cancer revealed two overlapping cellular networks where BMI1 and FSCN1 at the center of those networks. (b) Functional annotation of the gene list identified in BMI1 expressing colorectal cancer tumors revealed enrichment in genes involved in DNA binding and regulation of transcription. Data are presented as pie chart which illustrates the distribution of the top 20 pathway designations in BM1 expressing colorectal cancer tumors. The pie size corresponds to the number of matched entities in each pathway. (c) Functional annotation of the gene list identified in FSCN1 expressing colorectal cancer tumors revealed enrichment in genes involved in cell migration. Data are presented as pie chart which illustrates the distribution of the top 20 pathway designations in FSCN1 expressing colorectal cancer tumors. The pie size corresponds to the number of matched entities in each pathway</p></caption><graphic xlink:href="SJG-22-288-g007"/></fig><supplementary-material content-type="local-data" id="S1"><label>Supplement Table 1</label><caption><p>Genes positively correlating with BMI1 expression (pearson correlation &#x0003e; 0.3) in CRC</p></caption><media xlink:href="SJG-22-288_Suppl1.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><label>Supplement Table 2</label><caption><p>Genes positively correlating with FSCN1 expression (pearson correlation &#x0003e; 0.3) in CRC</p></caption><media xlink:href="SJG-22-288_Suppl2.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></sec><sec sec-type="discussion" id="sec1-3"><title>DISCUSSION</title><p>CRC is the third most common type of cancer in incidence and the fourth cause of cancer death world-wide, underscoring the need to identify novel biomarkers for early diagnosis, as well as for improved disease stratification and treatment choices. Treatment choice for CRC varies according to tumor location and stage at diagnosis.[<xref rid="ref20" ref-type="bibr">20</xref><xref rid="ref21" ref-type="bibr">21</xref>] Surgery is the most common treatment for early-stage (stage I and II) CRC. For patients with stage III CRC, surgery is frequently followed by short chemotherapy (approximately 6 months) to decrease the risk of recurrence.[<xref rid="ref22" ref-type="bibr">22</xref><xref rid="ref23" ref-type="bibr">23</xref>]</p><p>Chemotherapy is usually a common treatment for patients with advanced disease. The 5-year relative survival rates for patients with CRC is 64.9%, and when the disease spreads to distant organs, the 5-year survival rate drops to 12.5%.[<xref rid="ref24" ref-type="bibr">24</xref>] Therefore, there is a need for early diagnosis, better predictive markers, and to offer better treatment modalities for this disease.</p><p>Cumulative evidence revealed a functional involvement of different genes and signaling pathways in cancer development and resistance to standard therapies. For instance, the cancer stem cell (CSC) hypothesis proposes that tumors are heterogeneous and only a small fraction of tumor cells (CSC) is tumorigenic and those are the cells that resist standard therapies.[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref25" ref-type="bibr">25</xref>] BMI1 is a member of the PcG, which function by forming several multimeric polycomb repressive complexes, such as PRC1, and PRC2. PRC1, also known as the &#x0201c;maintenance complex,&#x0201d; contains the BMI1 proto-oncogene. In stem cells, PcG genes maintain stemness by repressing transcription of key stem cell genes, such as homeobox (Hox) genes, and by preventing senescence through repression of the INK4A locus.[<xref rid="ref26" ref-type="bibr">26</xref><xref rid="ref27" ref-type="bibr">27</xref>] In addition to their role during development of stem cells, several members of the PcG gene family are overexpressed in different cancer types. In particular, several studies correlated BMI1 overexpression with disease progression and poor clinical outcome.[<xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref>] We recently characterized a novel role for BMI1 in protecting cancer cells from P53-mediated apoptosis during radiation therapy, which would be concordant with the observed poor OS and DFS in the current study.[<xref rid="ref6" ref-type="bibr">6</xref>] Nonetheless, a number of studies implicated overexpression of BMI1 in the tumor-initiating cells (TI-C) of leukemia, brain, or breast cancers.[<xref rid="ref28" ref-type="bibr">28</xref><xref rid="ref29" ref-type="bibr">29</xref><xref rid="ref30" ref-type="bibr">30</xref>] Therefore, it could be postulated that BMI1 is conferring resistance in the subset of TI-Cs during conventional therapy, which would also be concordant with our findings in the current study. Consistent with its role in stem cell maintenance, our data has revealed that BMI1-expressing cells are enriched in zinc finger, DNA binding, and genes involved in transcriptional regulation [<xref ref-type="fig" rid="F5">Figure 5a</xref> and <xref ref-type="fig" rid="F5">b</xref>]. Therefore, it is plausible that the poor OS and DFS observed in BMI1<sup>high</sup> CRC patients can be attributed to the enrichment in a CSC phenotype.</p><p>On the other hand, our recent molecular profiling of CRC in Saudi Arabia has revealed multiple dysregulated pathways in CRC.[<xref rid="ref10" ref-type="bibr">10</xref>] Interestingly, our data revealed significant upregulation of FSCN1 in CRC, which would be consistent with the data presented in the current study from other datasets (GSE21510). Our current study has revealed enrichment in genes involved in cell migration in FSCN1<sup>high</sup> CRC tumors, which might explain the observed reduced OS and DFS in those patients [Figures <xref ref-type="fig" rid="F2">2</xref> and <xref ref-type="fig" rid="F3">3</xref>]. Interestingly, tumors expressing high levels of BMI1 and FSCN1 exhibited significant decline in OS and DSF compared to patients expressing either marker alone [<xref ref-type="fig" rid="F4">Figure 4</xref> vs. Figures <xref ref-type="fig" rid="F2">2</xref> and <xref ref-type="fig" rid="F3">3</xref>]. Therefore, our data suggest that tumors that exhibit a CSC phenotype (BMI1<sup>high</sup>) and a high migration and metastatic potential (FSCN1<sup>high</sup>) are the tumors that cause relapse faster than tumors lacking this phenotype.</p></sec><sec sec-type="conclusions" id="sec1-4"><title>CONCLUSION</title><p>Our data revealed poor OS and DFS in CRC patients overexpressing BMI1 or FSCN1 and suggest using combination of the two markers as a novel prognostic indicator in CRC. Targeting BMI1 and FSCN1 might provide potential therapeutic opportunity for CRC.</p><sec id="sec2-8"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec id="sec2-9"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ack><title>Acknowledgement</title><p>We would like to thank the college of medicine research center (CMRC) deanship for scientific research, King Saud University for their support.</p></ack><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Desantis</surname><given-names>C</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Colorectal cancer statistics, 2014</article-title><source>CA Cancer J Clin</source><year>2014</year><volume>64</volume><fpage>104</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">24639052</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Ahwal</surname><given-names>MS</given-names></name><name><surname>Shafik</surname><given-names>YH</given-names></name><name><surname>Al-Ahwal</surname><given-names>HM</given-names></name></person-group><article-title>First national survival data for colorectal cancer among Saudis between 1994 and 2004: What's next?</article-title><source>BMC Public Health</source><year>2013</year><volume>13</volume><fpage>73</fpage><pub-id pub-id-type="pmid">23351644</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>YB</given-names></name><name><surname>Pirrotta</surname><given-names>V</given-names></name></person-group><article-title>Polycomb silencing mechanisms and the management of genomic programmes</article-title><source>Nat Rev Genet</source><year>2007</year><volume>8</volume><fpage>9</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">17173055</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alajez</surname><given-names>NM</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Hui</surname><given-names>AB</given-names></name><name><surname>Bruce</surname><given-names>J</given-names></name><name><surname>Lenarduzzi</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>E</given-names></name><etal/></person-group><article-title>Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98</article-title><source>Cell Death Dis</source><year>2010</year><volume>1</volume><fpage>e85</fpage><pub-id pub-id-type="pmid">21368858</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chagraoui</surname><given-names>J</given-names></name><name><surname>H&#x000e9;bert</surname><given-names>J</given-names></name><name><surname>Girard</surname><given-names>S</given-names></name><name><surname>Sauvageau</surname><given-names>G</given-names></name></person-group><article-title>An anticlastogenic function for the Polycomb Group gene Bmi1</article-title><source>Proc Natl Acad Sci USA</source><year>2011</year><volume>108</volume><fpage>5284</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">21402923</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alajez</surname><given-names>NM</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Hui</surname><given-names>AB</given-names></name><name><surname>Yue</surname><given-names>S</given-names></name><name><surname>Ng</surname><given-names>R</given-names></name><name><surname>Lo</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Targeted depletion of BMI1 sensitizes tumor cells to P53-mediated apoptosis in response to radiation therapy</article-title><source>Cell Death Differ</source><year>2009</year><volume>16</volume><fpage>1469</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">19575017</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alajez</surname><given-names>NM</given-names></name></person-group><article-title>Cancer stem cells. From characterization to therapeutic implications</article-title><source>Saudi Med J</source><year>2011</year><volume>32</volume><fpage>1229</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">22159375</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>DW</given-names></name><name><surname>Tang</surname><given-names>HM</given-names></name><name><surname>Fan</surname><given-names>JW</given-names></name><name><surname>Yan</surname><given-names>DW</given-names></name><name><surname>Zhou</surname><given-names>CZ</given-names></name><name><surname>Li</surname><given-names>SX</given-names></name><etal/></person-group><article-title>Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer</article-title><source>J Cancer Res Clin Oncol</source><year>2010</year><volume>136</volume><fpage>997</fpage><lpage>1006</lpage><pub-id pub-id-type="pmid">20024662</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>ZK</given-names></name><name><surname>Yang</surname><given-names>JA</given-names></name><name><surname>Ye</surname><given-names>YL</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>LH</given-names></name><name><surname>Zhou</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Expression of Bmi-1 is a prognostic marker in bladder cancer</article-title><source>BMC Cancer</source><year>2009</year><volume>9</volume><fpage>61</fpage><pub-id pub-id-type="pmid">19228380</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vishnubalaji</surname><given-names>R</given-names></name><name><surname>Hamam</surname><given-names>R</given-names></name><name><surname>Abdulla</surname><given-names>MH</given-names></name><name><surname>Mohammed</surname><given-names>MA</given-names></name><name><surname>Kassem</surname><given-names>M</given-names></name><name><surname>Al-Obeed</surname><given-names>O</given-names></name><etal/></person-group><article-title>Genome-wide mRNA and miRNA expression profiling reveal multiple regulatory networks in colorectal cancer</article-title><source>Cell Death Dis</source><year>2015</year><volume>6</volume><fpage>e1614</fpage><pub-id pub-id-type="pmid">25611389</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Pinilla</surname><given-names>SM</given-names></name><name><surname>Sarri&#x000f3;</surname><given-names>D</given-names></name><name><surname>Honrado</surname><given-names>E</given-names></name><name><surname>Hardisson</surname><given-names>D</given-names></name><name><surname>Calero</surname><given-names>F</given-names></name><name><surname>Benitez</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>1533</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16533778</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qualtrough</surname><given-names>D</given-names></name><name><surname>Singh</surname><given-names>K</given-names></name><name><surname>Banu</surname><given-names>N</given-names></name><name><surname>Paraskeva</surname><given-names>C</given-names></name><name><surname>Pignatelli</surname><given-names>M</given-names></name></person-group><article-title>The actin-bundling protein fascin is overexpressed in colorectal adenomas and promotes motility in adenoma cells <italic>in vitro</italic></article-title><source>Br J Cancer</source><year>2009</year><volume>101</volume><fpage>1124</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19738613</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><etal/></person-group><article-title>Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin</article-title><source>Cancer Res</source><year>2014</year><volume>74</volume><fpage>2455</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">24599125</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Alesi</surname><given-names>GN</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Seo</surname><given-names>JH</given-names></name><etal/></person-group><article-title>The prometastatic ribosomal S6 kinase 2-cAMP response element-binding protein (RSK2-CREB) signaling pathway up-regulates the actin-binding protein fascin-1 to promote tumor metastasis</article-title><source>J Biol Chem</source><year>2013</year><volume>288</volume><fpage>32528</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">24085294</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Ou</surname><given-names>C</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><etal/></person-group><article-title>MicroRNA-145 inhibits tumour growth and metastasis in colorectal cancer by targeting fascin-1</article-title><source>Br J Cancer</source><year>2014</year><volume>110</volume><fpage>2300</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">24642628</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Dresdner</surname><given-names>G</given-names></name><name><surname>Gross</surname><given-names>B</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><etal/></person-group><article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal</article-title><source>Sci Signal</source><year>2013</year><volume>6</volume><fpage>pl1</fpage><pub-id pub-id-type="pmid">23550210</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Gross</surname><given-names>BE</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><etal/></person-group><article-title>The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data</article-title><source>Cancer Discov</source><year>2012</year><volume>2</volume><fpage>401</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">22588877</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukamoto</surname><given-names>S</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Iida</surname><given-names>S</given-names></name><name><surname>Ishiguro</surname><given-names>M</given-names></name><name><surname>Mogushi</surname><given-names>K</given-names></name><name><surname>Mizushima</surname><given-names>H</given-names></name><etal/></person-group><article-title>Clinical significance of osteoprotegerin expression in human colorectal cancer</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><fpage>2444</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">21270110</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukaka</surname><given-names>MM</given-names></name></person-group><article-title>Statistics corner: A guide to appropriate use of correlation coefficient in medical research</article-title><source>Malawi Med J</source><year>2012</year><volume>24</volume><fpage>69</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">23638278</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoen</surname><given-names>RE</given-names></name><name><surname>Pinsky</surname><given-names>PF</given-names></name><name><surname>Weissfeld</surname><given-names>JL</given-names></name><name><surname>Yokochi</surname><given-names>LA</given-names></name><name><surname>Church</surname><given-names>T</given-names></name><name><surname>Laiyemo</surname><given-names>AO</given-names></name><etal/></person-group><article-title>Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy</article-title><source>New Engl J Med</source><year>2012</year><volume>366</volume><fpage>2345</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">22612596</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoney</surname><given-names>A</given-names></name><name><surname>Isikli</surname><given-names>L</given-names></name></person-group><article-title>Preoperative chemoradiation in locally advanced rectal cancer: A comparison of bolus 5-fluorouracil/leucovorin and capecitabine</article-title><source>Saudi J Gastroenterol</source><year>2014</year><volume>20</volume><fpage>102</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">24705147</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benson</surname><given-names>AB</given-names><suffix>3rd</suffix></name><name><surname>Schrag</surname><given-names>D</given-names></name><name><surname>Somerfield</surname><given-names>MR</given-names></name><name><surname>Cohen</surname><given-names>AM</given-names></name><name><surname>Figueredo</surname><given-names>AT</given-names></name><name><surname>Flynn</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>3408</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">15199089</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuebler</surname><given-names>JP</given-names></name><name><surname>Wieand</surname><given-names>HS</given-names></name><name><surname>O'Connell</surname><given-names>MJ</given-names></name><name><surname>Smith</surname><given-names>RE</given-names></name><name><surname>Colangelo</surname><given-names>LH</given-names></name><name><surname>Yothers</surname><given-names>G</given-names></name><etal/></person-group><article-title>Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>2198</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">17470851</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeSantis</surname><given-names>CE</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name><name><surname>Mariotto</surname><given-names>AB</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Stein</surname><given-names>KD</given-names></name><name><surname>Kramer</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Cancer treatment and survivorship statistics, 2014</article-title><source>CA Cancer J Clin</source><year>2014</year><volume>64</volume><fpage>252</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">24890451</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreso</surname><given-names>A</given-names></name><name><surname>Dick</surname><given-names>JE</given-names></name></person-group><article-title>Evolution of the cancer stem cell model</article-title><source>Cell Stem Cell</source><year>2014</year><volume>14</volume><fpage>275</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">24607403</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lessard</surname><given-names>J</given-names></name><name><surname>Schumacher</surname><given-names>A</given-names></name><name><surname>Thorsteinsdottir</surname><given-names>U</given-names></name><name><surname>van Lohuizen</surname><given-names>M</given-names></name><name><surname>Magnuson</surname><given-names>T</given-names></name><name><surname>Sauvageau</surname><given-names>G</given-names></name></person-group><article-title>Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell proliferation</article-title><source>Genes Dev</source><year>1999</year><volume>13</volume><fpage>2691</fpage><lpage>703</lpage><pub-id pub-id-type="pmid">10541555</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biehs</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>JK</given-names></name><name><surname>Strauli</surname><given-names>NB</given-names></name><name><surname>Sangiorgi</surname><given-names>E</given-names></name><name><surname>Jung</surname><given-names>H</given-names></name><name><surname>Heber</surname><given-names>RP</given-names></name><etal/></person-group><article-title>BMI1 represses Ink4a/Arf and Hox genes to regulate stem cells in the rodent incisor</article-title><source>Nat Cell Biol</source><year>2013</year><volume>15</volume><fpage>846</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">23728424</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lessard</surname><given-names>J</given-names></name><name><surname>Sauvageau</surname><given-names>G</given-names></name></person-group><article-title>Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells</article-title><source>Nature</source><year>2003</year><volume>423</volume><fpage>255</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">12714970</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Tunici</surname><given-names>P</given-names></name><name><surname>Ng</surname><given-names>H</given-names></name><name><surname>Abdulkadir</surname><given-names>IR</given-names></name><etal/></person-group><article-title>Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma</article-title><source>Mol Cancer</source><year>2006</year><volume>5</volume><fpage>67</fpage><pub-id pub-id-type="pmid">17140455</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Dontu</surname><given-names>G</given-names></name><name><surname>Mantle</surname><given-names>ID</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Ahn</surname><given-names>NS</given-names></name><name><surname>Jackson</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>6063</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">16778178</pub-id></element-citation></ref></ref-list></back></article>